Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Articles: Therapeutics, Targets, and Development

Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

Jorge L. Martínez-Torrecuadrada, Lawrence H. Cheung, Paula López-Serra, Rodrigo Barderas, Marta Cañamero, Sergio Ferreiro, Michael G. Rosenblum and J. Ignacio Casal
Jorge L. Martínez-Torrecuadrada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence H. Cheung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula López-Serra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodrigo Barderas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Cañamero
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Ferreiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael G. Rosenblum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Ignacio Casal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-07-0394 Published April 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Production of recombinant rGel-based immunotoxins targeting FGFR3. A, schematic representation of anti-FGFR3/rGel fusion toxins. VH and VL represent variable region heavy and light chains, respectively, of the FGFR3-specific scFv from clone 3C; (G4S)3, linker consisting of four glycine and one serine residues repeated three times. 218L and SSGSGSA or G4S are different linkers between VL and VH and between scFv and rGel, respectively. B, Coomassie-stained SDS-PAGE under reducing conditions of the purified FGFR3-specific scFv 3C, immunotoxins 3C/rGel and 3CF/rGel, and rGel alone. C, affinity constants of immunotoxins compared with the parental scFv 3C by surface plasmon resonance (BIAcore). The response in resonance units (RU) was recorded as a function of time. Sensorgram overlays show the binding of constructs to immobilized FGFR3 on CM5 chips measured at a constant flow rate of 20 μL/min. The curves are labeled with the samples tested: 3C, 3C/rGel, 3CF/rGel, and rGel alone as a negative control. Inset, affinity constants (Kd in nmol/L) for each construct.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    In vitro cytotoxicity and antibody-mediated internalization of FGFR3-specific immunotoxins. A, FGFR3-overexpressing RT112 cells were treated with various concentrations of 3C/rGel, 3CF/rGel, or free rGel for 72 h. Cell viability indicates the percentage of cells in drug-treated wells compared with that of control (untreated) wells. Points, mean of triplicate determinations; bars, SD. B, FGFR3 silencing by using a pool of siRNA duplexes specific for FGFR3. RT112 cells were either transfected with nonspecific siRNA [si(nonspecific)] or with FGFR3-specific siRNA [si(FGFR3)] duplexes as described in Materials and Methods. Left, FGFR3 transcript levels were measured by real-time reverse transcription-PCR at 24 h post-transfection. Results are given as percentage of the average of the FGFR3 mRNA level in si(FGFR3)-transfected cells (gray column) relative to that in si(nonspecific)-transfected cells (black column), which corresponded to 100%. Bars, SD. Right, Western blot analysis on lysates of the same aliquots of siRNA-transfected cells confirmed that si(FGFR3) significantly inhibited FGFR3 protein expression. α-Tubulin was detected as a loading control. C, cytotoxicity of 3C-rGel on FGFR3-silenced cells. RT112 cells transfected with si(FGFR3) (♦), si(nonspecific) (▪), or mock (▴) were treated with various concentrations of 3C/rGel (solid lines) or free rGel (dashed lines) at 24 h post-transfection. After 72 h of exposure, cell proliferation was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Cell viability indicates the percentage of cells in drug-treated wells compared with that of control (untreated) wells. Points, mean of three replicates; bars, SD. D, antibody-mediated internalization into RT112 cells was visualized by confocal microscopy. RT112 cells were incubated for 1 h with 50 nmol/L of the corresponding immunotoxin, 3C/rGel or 3CF/rGel, or rGel and saline as controls. After surface-bound proteins were stripped by acid wash, the cells were then processed and stained for rGel using a rabbit polyclonal anti-rGel antibody followed by Cy3-coupled anti-rabbit IgG as detection reagent. Nuclei were counterstained with DAPI. Images were taken with a confocal microscope at ×63 amplification. Bar, 8 μm.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Apoptosis induction in FGFR3-expressing bladder carcinoma cell lines by scFv and immunotoxins. A, RT112 cells were treated with 0.2 μmol/L of each construct and, at the indicated time point, were stained with Annexin V-FITC and PI followed by flow cytometry analysis. Numbers in the top of quadrants of each plot represent the percentage of the Annexin V–positive or Annexin V–negative and PI-positive or PI-negative cells. Bottom, percentage of Annexin V–positive cells at 24, 48, and 72 h for each construction tested. B, Western blot showing the level of FGFR3 expression in RT4 cells compared with that in RT112 cells using FGFR3-specific antibodies. α-Tubulin was detected as a loading control. C, RT4 cells were treated with 0.2 μmol/L 3C-rGel or rGel as a control and, at the indicated time point, were stained with Annexin V-FITC and PI followed by flow cytometry analysis.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    In vivo antitumor activity of the FGFR3-specific scFv and immunotoxins on established RT112 xenografts. Groups of severe combined immunodeficient mice bearing RT112 tumors were treated i.v. with rGel-derived immunotoxins at 50 mg/kg, scFv 3C and free rGel at 25 mg/kg, or saline in alternating days for 2 wk and tested for tumor growth delay of established tumors. A, tumor volumes were measured with calipers about twice a week. Data show two independent experiments each done with four to six mice. Points, mean tumor volume versus time; bars, SD. Dotted line, endpoint size of tumors (1,500 mm3). X axis, arrows, inoculation days. B, percentage of surviving mice are graphed over time.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Histopathology analysis of 3C/rGel-treated RT112-derived tumor xenografts. 3C/rGel- and saline-treated tumors were excised at 25 d post-implantation and, 1 d after the final dose, formalin-fixed, paraffin-embedded, and stained for histopathology characterization. A, H&E tumor sections (magnification, ×200) showed more extensive areas of necrosis (arrowhead) in 3C/rGel-treated animals than in the saline control. B, CD34 staining of tumor sections was used to assess blood vessel density (brown, endothelial cells; magnification, ×200). C, Ki-67 staining was used to assess tumor cell proliferation (brown, proliferating cells; magnification, ×400). Columns, mean percentage of proliferating (Ki-67-positive) cells; bars, SD. D, caspase-3-active immunostaining was used to assess the influence of 3C/rGel treatment compared with saline on apoptosis (brown, apoptotic cells; magnification, ×400). Columns, mean percentage of apoptotic (caspase-3-active-positive) cells; bars, SD. *, P < 0.0001 (Student's t test).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Immunolocalization of FGFR3 in 3C/rGel- and saline-treated RT112-derived tumors. 3C/rGel- and saline-treated tumors were excised at 25 d post-implantation and, 1 d after the final dose, formalin fixed, paraffin-embedded, and stained with anti-FGFR3 antibody. A, tumor sections of RT112-derived xenografts treated with either 3C/rGel (top) or vehicle (bottom) were used to evaluate the presence and location of FGFR3 on tumor cells by immunohistochemistry (brown, FGFR3-positive cells; left, magnification, ×100; right, magnification, ×400). B, immunofluorescence with anti-FGFR3 antibody (green) of tumor sections from 3C/rGel-treated showing nuclear staining (top) and nontreated with cytoplasm staining (bottom) xenografts (magnification, ×200). Sections were counterstained with DAPI (blue) to visualize the nuclei. Column 3, merged images of the labeled cells. Insets, a close-up with intense nuclear staining.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (4)
April 2008
Volume 7, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
Citation Tools
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
Jorge L. Martínez-Torrecuadrada, Lawrence H. Cheung, Paula López-Serra, Rodrigo Barderas, Marta Cañamero, Sergio Ferreiro, Michael G. Rosenblum and J. Ignacio Casal
Mol Cancer Ther April 1 2008 (7) (4) 862-873; DOI: 10.1158/1535-7163.MCT-07-0394

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
Jorge L. Martínez-Torrecuadrada, Lawrence H. Cheung, Paula López-Serra, Rodrigo Barderas, Marta Cañamero, Sergio Ferreiro, Michael G. Rosenblum and J. Ignacio Casal
Mol Cancer Ther April 1 2008 (7) (4) 862-873; DOI: 10.1158/1535-7163.MCT-07-0394
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells
  • Inhibition of cervical cancer cell growth by human papillomavirus virus–like particles packaged with human papillomavirus oncoprotein short hairpin RNAs
  • Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement